top of page


Our lead technology platform positions us to have a meaningful impact in multiple diseases, starting with Alzheimer’s

Our lead technology, APEX, is a diagnostic platform that is uniquely capable of detecting very low levels of nanoscale, disease-specific protein states in blood with high accuracy. 


APEX uses a proprietary sensor platform and optical amplification to identify diverse protein biomarkers associated with multiple diseases, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, glioblastoma, pancreatic cancer and heart disease. 


APEX Enables Detection of EV-Protein Aggregates


Image of Sensor in a Chip
Image of APEX Chip

Size-matched nanoholes in optimized geometry


Sensitive and enhanced detection of EVs

APEX chip surface with green light signal
APEX chip surface with red light signal

Healthy: green light signal

Diseased: red-shifted light signal


Biomarker co-localization: Optical deposits form

Direct detection of EV-protein aggregates in native blood samples

Case in Point: Alzheimer’s Disease 


In individuals with Alzheimer’s disease, “sticky” amyloid beta (Aβ) molecules accumulate in the brain. These sticky molecules form aggregates and deposits, often referred to as “amyloid plaques,” that disrupt cell function. 


The APEX platform has demonstrated the ability to directly and accurately detect Aβ molecules in the blood. Current diagnostics have had limited success in identifying and analyzing these nanoscale proteins, which provide crucial disease insights.

Diseased Cell

Extracellular vesicles (EVs)

  • Nanoscale lipid vesicles

  • Cross the blood-brain barrier

  • Rich source of molecular biomarkers (cell surrogates, sticky proteins)

  • Aggregated or “sticky” Aβ molecules in the brain bind to lipid particles known as extracellular vesicles (EVs).


  • Scarce levels of these EVs pass through the blood-brain barrier into the bloodstream. 

  • APEX is the only diagnostic platform that specifically detects low concentrations of these EV biomarkers and their Aβ cargo.

Published data confirm that the APEX approach: 

  • Provides accurate detection and clinical subtyping of Alzheimer’s disease equivalent to the current gold standard, PET imaging.

  • Significantly improves upon all other available blood-based tests.


We are actively partnering with biopharma companies and researchers to validate the performance of the APEX amyloid positivity test and bring it to market. 

Interested in learning more about APEX? 

Thanks for your interest in Sunbird Bio!

bottom of page